BLCONYSEOphthalmic GoodsFiscal year ends December 31
Bausch & Lomb Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$16.61+0.12 (+0.73%)
Close on Oct 19, 2026
- Market cap
- $5.93B
- P/E (TTM)
- –
- Dividend yield
- –
Bausch & Lomb Corp revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Vision Care | $2.92B | $2.74B | $2.54B | $2.37B | $2.33B | $2.11B | 57.3% | +6.7% |
| Pharmaceuticals | $1.28B | $1.21B | $836.00M | $681.00M | $720.00M | – | 25.2% | +6.2% |
| Surgical | $894.00M | $843.00M | $767.00M | $718.00M | $718.00M | $577.00M | 17.5% | +6.0% |
| Ophthalmic Pharmaceuticals | – | – | – | $677.00M | $704.00M | $726.00M | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | YoY |
|---|---|---|---|---|---|---|---|
| Vision Care | $849.00M | $808.00M | $689.00M | $636.00M | $576.00M | $579.00M | +5.1% |
| Pharmaceuticals | $258.00M | $256.00M | $241.00M | $203.00M | $301.00M | – | +0.8% |
| Surgical | $18.00M | $44.00M | $50.00M | $42.00M | $75.00M | $18.00M | -59.1% |
| Ophthalmic Pharmaceuticals | – | – | – | $202.00M | $290.00M | $302.00M | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Product sales | $5.08B | $4.77B | $4.13B | $3.75B | $3.74B | $3.38B | 99.6% | +6.4% |
| Devices | $1.92B | $1.80B | $1.65B | $1.57B | $1.60B | $1.31B | 37.7% | +6.8% |
| OTC | $1.83B | $1.72B | $1.61B | $1.46B | $1.39B | $1.31B | 36.0% | +6.4% |
| Pharmaceuticals | $1.08B | $969.00M | $618.00M | $468.00M | $493.00M | $508.00M | 21.2% | +11.6% |
| Branded and Other Generics | $243.00M | $281.00M | $252.00M | $245.00M | $254.00M | $249.00M | 4.8% | -13.5% |
| Other revenues | $21.00M | $17.00M | $15.00M | $22.00M | $28.00M | $31.00M | 0.4% | +23.5% |
| Other revenues | $21.00M | $17.00M | $15.00M | $22.00M | $28.00M | $31.00M | 0.4% | +23.5% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| U.S. and Puerto Rico | $2.55B | $2.41B | $1.93B | $1.70B | $1.62B | $1.56B | 49.9% | +5.5% |
| Other | $777.00M | $712.00M | $655.00M | $616.00M | $572.00M | $516.00M | 15.2% | +9.1% |
| China | $358.00M | $358.00M | $344.00M | $343.00M | $390.00M | $280.00M | 7.0% | 0.0% |
| France | $246.00M | $227.00M | $210.00M | $195.00M | $201.00M | $174.00M | 4.8% | +8.4% |
| Japan | $186.00M | $180.00M | $187.00M | $192.00M | $224.00M | $220.00M | 3.6% | +3.3% |
| Germany | $164.00M | $152.00M | $147.00M | $138.00M | $149.00M | $137.00M | 3.2% | +7.9% |
| Russia | $148.00M | $120.00M | $106.00M | $132.00M | $116.00M | $102.00M | 2.9% | +23.3% |
| United Kingdom | $137.00M | $132.00M | $121.00M | $108.00M | $111.00M | $84.00M | 2.7% | +3.8% |
| Canada | $135.00M | $127.00M | $110.00M | $101.00M | $101.00M | $92.00M | 2.6% | +6.3% |
| Italy | $102.00M | $91.00M | $82.00M | $72.00M | $75.00M | $67.00M | 2.0% | +12.1% |
| Spain | $101.00M | $92.00M | $85.00M | $77.00M | $80.00M | $66.00M | 2.0% | +9.8% |
| Poland | $75.00M | $65.00M | $51.00M | $44.00M | $42.00M | $36.00M | 1.5% | +15.4% |
| Mexico | $75.00M | $75.00M | $68.00M | $55.00M | $40.00M | $32.00M | 1.5% | 0.0% |
| South Korea | $51.00M | $47.00M | $46.00M | $44.00M | $46.00M | $48.00M | 1.0% | +8.5% |
| Belarus | – | – | – | $8.00M | $7.00M | $8.00M | – | – |
| Ukraine | – | – | – | $7.00M | $12.00M | $14.00M | – | – |
From the segment and revenue-disaggregation notes of Bausch & Lomb's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.